Literature DB >> 9163569

Dual effects of auranofin on prostaglandin E2 production by rat peritoneal macrophages.

M Yamashita1, H Niki, M Yamada, M Watanabe-Kobayashi, S Mue, K Ohuchi.   

Abstract

Incubation of rat peritoneal macrophages in medium containing various concentrations of auranofin (1, 3 and 10 microM) increased prostaglandin E2 production at 4 h in a concentration-dependent manner, in accordance with the increase in the release of [3H]arachidonic acid from membrane phospholipids. However, at 20 h, no stimulation of prostaglandin E2 production by auranofin was observed. When the peritoneal macrophages were incubated in the presence of 12-O-tetradecanoylphorbol 13-acetate (TPA), thapsigargin or A23187, prostaglandin E2 production at 4 and 20 h was enhanced. The stimulator-induced prostaglandin E2 production at 20 h was suppressed by 10 microM of auranofin. Western blot analysis demonstrated that auranofin inhibited the induction of cyclooxygenase 2 by TPA, thapsigargin or A23187 at 4 and 20 h. The level of cyclooxygenase 1 did not change by treatment with these stimulators in the presence or absence of auranofin. These findings suggest that auranofin has dual effects on prostaglandin E2 production: without stimulation, auranofin increases prostaglandin E2 production at 4 h due to the increased release of arachidonic acid which is converted to prostaglandin E2 mainly by cyclooxygenase 1, but inhibits the stimulator-induced late-phase prostaglandin E2 production by inhibiting the induction of cyclooxygenase 2.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163569     DOI: 10.1016/s0014-2999(97)00118-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  The biological activity of auranofin: implications for novel treatment of diseases.

Authors:  J M Madeira; D L Gibson; W F Kean; A Klegeris
Journal:  Inflammopharmacology       Date:  2012-09-11       Impact factor: 4.473

Review 2.  Auranofin and Pharmacologic Ascorbate as Radiomodulators in the Treatment of Pancreatic Cancer.

Authors:  Garett J Steers; Gloria Y Chen; Brianne R O'Leary; Juan Du; Hannah Van Beek; Joseph J Cullen
Journal:  Antioxidants (Basel)       Date:  2022-05-14

Review 3.  Aspirin Intolerance: Experimental Models for Bed-to-Bench.

Authors:  Masamichi Yamashita
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.